 Kalvista Pharmaceuticals NASDAQ:KALV was downgraded by Zacks Investment Research from a buy rating to a hold rating in a research note issued on Saturday, Zacks.com reports. According to Zacks, KalVista Pharmaceuticals, Inc. is a pharmaceuticals company. It engages in discovery, development and commercialization of small molecule protease inhibitors for diseases with significant unmet need. Its ... 